5300 MEMORIAL DRIVE, HOUSTON, TX
Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
News, Underwriting Agreement, Securities Holder Rights or Indentures, Material Contracts
Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
Investor Presentation
Reg. FD
Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
Q2
Q1
Amended Annual Report
FY 2025
Q3
Prospectus filed pursuant to Rule 424(b)(5)
Amended Registration Statement for Securities
S-1
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
PRER14A
Schedule 13D - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload